NCT07166783已完成1 期
Pharmacokinetics, Pharmacological Effects and Safety of Single Dose of 7.5mg Tolvaptan Tablet in Healthy Male Subjects
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 主要终点
- Tolvaptan PK parameter
研究概览
简要总结
Pharmacokinetics, pharmacological effects and safety of single dose of 7.5mg Tolvaptan tablet in healthy male subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male, signing the informed consent form;
- •At the time of signing the informed consent form, aged between 18 and 40 years old (inclusive);
- •Body weight no less than 50kg, body mass index within the range of 19 to 24 (inclusive);
- •Proven to be a healthy subject based on the results of medical history, serological tests (HIV antibody, HBsAg, HCV antibody and syphilis antibody), physical examination, vital signs (temperature, blood pressure, pulse), 12-lead electrocardiogram, and laboratory tests (blood routine, blood biochemistry, coagulation function and urine routine).
排除标准
- •Those with a history of heart, liver, kidney, digestive tract, metabolic disorders, respiratory, blood, mental or nervous system diseases, or those judged by the physician as unsuitable.
- •Those with a history of clinically significant arrhythmias of any type, including a family history of genetic diseases (relatives with a history of arrhythmias with genetic predisposition), such as rapid and slow types, including atrioventricular block, sinus arrest, supraventricular tachycardia, etc.
- •Those with a history of drug or other substance allergies, allergic constitution or tendency.
- •Those known to be intolerant to the components of the test drug (including lactose), such as those with rare hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
- •Those with various urinary disorders (such as frequent urination or difficulty in urination, etc.).
- •Those who smoke, are alcoholics or have other drug dependencies.
- •Those who have donated blood or lost an equivalent amount of blood (>350 ml) within 12 weeks before enrollment.
- •Those who have participated in any drug trials within 12 weeks before enrollment.
- •Those who have taken any preventive or therapeutic drugs within the past 2 weeks.
- •Those who have consumed grapefruit or grapefruit-containing foods within one week before taking the drug.
- •Those whose diet is significantly deviated from normal protein, carbohydrate and fat intake as judged by the investigator (such as vegetarians or absolute vegetarians).
- •Those with a history of orthostatic hypotension (a drop in blood pressure of ≥20/10 mmHg when changing from a lying to a standing position, accompanied by symptoms such as dizziness), orthostatic dizziness, syncope, fainting or vertigo.
- •Those whose resting pulse rate is less than 55 beats per minute or more than 90 beats per minute after sitting quietly for more than 3 minutes.
- •Those whose sitting systolic blood pressure is less than 100 mmHg or more than 140 mmHg, or whose diastolic blood pressure is less than 60 mmHg or more than 90 mmHg after sitting quietly for more than 3 minutes.
- •Those with clinically significant 12-lead electrocardiogram changes.
- •Those with clinically significant physical examination abnormalities.
- •Those with positive results for HIV antibody, HBsAg, HCV antibody or syphilis antibody tests.
- •Other conditions judged by the researcher as potentially affecting the subject's completion of the trial.
研究组 & 干预措施
7.5mg Tolvaptan single dose
Experimental
干预措施: Tolvaptan (Drug)
结局指标
主要结局
Tolvaptan PK parameter
时间窗: On Day 1 pre-dose and post-dose 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours
apparent volume of distribution (Vd/F)
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Efficacy and safety of administration of Tolvaptan twice daily in hospitalized acute heart failure patientsJPRN-UMIN000021110Japanese Red Cross Nagoya First Hospital50
尚未招募
不适用
Pharmacokinetics of Tolvaptan:Influence of portal hypertensioDecompensated cirrhosisJPRN-UMIN000017284Juntendo University Nerima Hospital Department of Gastroenterology40
已完成
1 期
Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy MaleHealthyNCT01014416Korea Otsuka Pharmaceutical Co., Ltd.46
终止
不适用
Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care PatientsBrain InjuryHyponatremiaNCT02215148University of North Carolina, Chapel Hill1
已完成
2 期
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDAutosomal Dominant Polycystic Kidney DiseaseNCT01210560Otsuka Pharmaceutical Development & Commercialization, Inc.25